Who can take part?

• Eligible subjects must be ≥40 years of age.
• Have a confirmed diagnosis of IPF through HRCT or a surgical lung biopsy. 
• FVC ≥45% predicted.
• Subjects on Pirfenidone or Nintedanib must be on a stable and optimized dose for ≥30 days prior to Baseline.

What is involved for you?

The study will run for about 58 weeks and will entail at least 8 visits to the clinical trials unit.
Patients will be required to complete the below;

• Informed Consent
• Eligibility Check
• Medical History, History of IPF and Demographics
• Physical Examination
• Vital Signs
• Urine Pregnancy Test
• ECG or EKG
• Blood Tests
• Study Specific Questionnaires
• Lung Function Tests; Spirometry & DLCO Testing
• Health and Medication Chec
• Participant Device Training
• Complete a Study Drug Diary
• Study Drug Administration
• HRCT
• Weekly Telephone/ Email Contact

Trial dates

September 2022 - November 2024